Kaiting Yang

Kaiting Yang’s practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance. Kaiting has actively participated in pre-IPO financing and initial public offering of biotech company seeking to list on the HKEX, and regulatory compliance for biotech company listed on the HKEX, in particular, Ascletis Pharma Inc. (HKEX: 1672), the first pre-revenue biotech company listed on the HKEX under the new listing regime for companies from emerging and innovative sectors.

Prior to joining Cooley, Kaiting has worked at the Hong Kong office of another leading US law firm.

Kaiting is a native Mandarin speaker and is fluent in English and Cantonese.

Representative Matters:

Primary Offering, Pre-IPO Investment and PIPE

• Advised YH Entertainment, the largest artist management company in China, on its HK$490 million IPO on HKEX 
• Joint sponsors and underwriters Citi and Huatai International on Cryofocus Medtech's HK$210 million IPO and listing on HKEX.
• STAR CM, a variety program intellectual property creator and operator, on its HK$390 million IPO and listing on HKEX.
• CICC, Citigroup and China Renaissance as joint sponsors on the US$285 million H shares IPO and listing of Huitongda Network Co., Ltd., a leading e-commerce company backed by Alibaba, on HKEX.
• Asymchem, a leading contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its US$818 million IPO and listing on the Hong Kong Stock Exchange. This is the largest healthcare HK IPO in 2021. 
• CICC, Citigroup and China Renaissance as joint sponsors on the US$285 million H shares IPO and listing of Huitongda Network Co., Ltd., a leading e-commerce company backed by Alibaba, on HKEX.
• Keymed Biosciences, a China-based biotechnology company focused on in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas, in its US$400 million Hong Kong IPO and global offering
• CStone Pharmaceuticals (HKEX: 2616) in its strategic collaboration with Pfizer Inc. (NYSE: PFE) which involves a 200 million equity investment by Pfizer in CStone, a collaboration for the development and commercialization of CStone’s core product (CS1001, PD-L1 antibody) in mainland China, and a framework to bring additional oncology assets to the Greater China market
• EHang, a world’s leading autonomous aerial vehicle technology platform company, in its initial public offering of American depositary shares and listing on Nasdaq
• Fangdd Network Technology, one of China’s largest online real estate platforms, in its initial public offering of American depositary shares and listing on Nasdaq
• Alphamab Oncology, a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in biospecifics and protein engineering, in its Series B Financing and US$234 million Hong Kong IPO and global offering
• Chinese property developer on its proposed IPO on the HKEX and global offering
• CLSA Limited as the Placing Agent in the placing of existing shares and top-up subscription of new shares in China New Higher Education Group Limited in the amount of HK$393 million
• ABCI Capital Limited and China Securities (International) Corporate Finance Company Limited as the underwriters and Joint Sponsors and other underwriters in the US$503 million Hong Kong IPO on the HKEX of Bank of Jiujiang Co., Ltd.
• China Everbright Greentech Limited, a subsidiary of China Everbright Group involving in business segments including waste to energy, water treatment and solar energy, on its spin-off listing and US$424 million Hong Kong IPO on the HKEX
• China International Capital Corporation, a leading China-based investment bank, in its US$708 million Hong Kong IPO and global offering
• BofA Merrill Lynch and Morgan Stanley as underwriters in the US$355 million Regulation S and 144A International offering of ordinary shares by Star Petroleum Refinery Corporation Limited in connection with its Thai IPO

Listed issuer’s Compliance

• Ascletis Pharma Inc. (HKEX: 1672) on its Hong Kong compliance matters
• Hilong Holding Limited (HKEX: 1623) on its Hong Kong compliance matters
• CNOOC Limited (HKEX: 0883) on its Hong Kong compliance matters
• Shanghai Yongda Automobiles Services Holdings Limited (HKEX: 3669) on its Hong Kong compliance matters and its spin-off for its proposed A share offering
• Mongolia Mining Corporation (HKEX: 0975) on its Hong Kong compliance matters
• Longfor Properties Co. Ltd. (HKEX: 0960) on its compliance obligations as listed issuer in its proposed debt offering

Debt Securities Offering

• Joint Lead Managers including Credit Suisse, Bank of China and Standard Chartered Banks on the USD bonds issuance of RMB1,850,000,000 issued by Tsinghua Unigroup Group
• Bank of Communications Financial Leasing Co., Ltd. on the US$1,000,000,000 Guaranteed MTN Programme and drawdown from the Programme
• The Ministry of Finance for the People’s Republic of China on its first USD sovereign bonds issuance of US$1,000,000,000 Bonds
• The Ministry of Finance for the People’s Republic of China on its RMB bonds issuance
• Arrangers/Dealers including Goldman Sachs, Haitong Securities, Standard Chartered Bank and Bank of China on the update of the US$6,000,000,000 Guaranteed MTN Programme issued by Beijing Infrastructure Investment Group and drawdown from the Programme
• Zhejiang Geely Automotive on its US$400,000,000 Credit Enhanced Green Bonds Offering

High-Yield

• Joint Lead Managers including J.P. Morgan, Credit Suisse and Deustche Bank on the US$1,000,000,000 High-yield Senior Notes issued by Evergrande Real Estate Group
• Credit Suisse and Nomura as Joint Bookrunners and Joint Lead Managers on the US$400,000,000 High-yield Senior Notes issued by West China Cement Limited